Press Releases

INOVIO to Present Three Posters at IDWeek 2021

Posted on September 29, 2021

INOVIO Receives Regulatory Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800, in Mexico

Posted on September 22, 2021

INOVIO Receives Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800

Posted on August 26, 2021

INOVIO Reports Second Quarter 2021 Financial Results

Posted on August 9, 2021

INOVIO and Advaccine Receive Regulatory Allowance for Two Heterologous Prime-Boost Clinical Trials in China Using INO-4800, INOVIO’s COVID-19 DNA Vaccine Candidate

Posted on August 9, 2021

INOVIO Doses First Participant in Phase 2 Trial for its DNA Vaccine Against Middle East Respiratory Syndrome (MERS), a Coronavirus Disease

Posted on August 4, 2021

INOVIO to Report Second Quarter 2021 Financial Results on August 9, 2021

Posted on July 26, 2021

INOVIO Expands Partnership with Advaccine to Conduct Global Phase 3 Efficacy Trial of COVID-19 DNA Vaccine Candidate, INO-4800

Posted on June 8, 2021

INOVIO to Present at the Jefferies 2021 Virtual Healthcare Conference

Posted on May 25, 2021

INOVIO Announces Appointment Of Roger Dansey, M.D., to its Board of Directors

Posted on May 17, 2021

© Copyright 2025 INOVIO Pharmaceuticals. All rights reserved.